Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135599 | 0.93 | HTR2C (0.32) | HTR2CSLC6A4ALDH1A1RORCKDM4E | |
| SCHEMBL4127365 | 0.93 | SCN9A (0.35) | HTR2CSLC6A4ALDH1A1RORCKDM4E | |
| SCHEMBL4123906 | 0.93 | SPR (0.35) | HTR2CSLC6A4ALDH1A1KDM4EMEN1 | |
| SCHEMBL4123622 | 0.89 | MDM2 (0.36) | HTR2CSLC6A4ALDH1A1RORCMEN1 | |
| SCHEMBL4118486 | 0.89 | GRIN2B (0.32) | HTR2CSLC6A4MEN1KMT2A | |
| SCHEMBL3700534 | 0.88 | HTR2C (0.45) | HTR2CSLC6A4ALDH1A1 | |
| SCHEMBL4131517 | 0.88 | GPBAR1 (0.33) | HTR2CSLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL3700538 | 0.87 | — | — | |
| SCHEMBL2838662 | 0.87 | SLC16A3 (0.38) | HTR2CSLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL4125525 | 0.86 | CNR1 (0.35) | HTR2CSLC6A4KCNQ3KCNQ2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HTR2C 2565/4885SLC6A4 3372/4885KCNQ3 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.